GSK — GLAXOSMITHKLINE PLC ADR (Healthcare >> Drug Manufacturers - General)
GSK FAQ
What is GSK's P/E ratio?
GLAXOSMITHKLINE PLC ADR (GSK) currently trades at a P/E ratio of 16.86.
What is GSK's ROE?
GLAXOSMITHKLINE PLC ADR reports a Return on Equity (ROE) of 24.76%.
What is GSK's dividend yield?
GLAXOSMITHKLINE PLC ADR offers a dividend yield of 3.68%.
What is GSK's Deepscope Quality Score?
Deepscope rates GSK's overall financial quality at 62 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy GSK?
Deepscope's AI Timing Score for GSK is 26 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does GSK belong to?
GLAXOSMITHKLINE PLC ADR is classified under the Healthcare >> Drug Manufacturers - General sector on the NYSE exchange.
|
USD 49.72
Price
0.72
(1.47%)
Day Change
|
|
|---|
GSK มีคุณภาพโดยรวมพอใช้ ( คะแนนปัจจัยพื้นฐาน = 62) และ จังหวะเข้าซื้อ ...(ล็อกอินเพื่อดู)...
- Signal
- NEUTRAL
- Signal Description
- Company financial health is OK
- Reason
-
อัตราเร่งของการเติบโตของอัตราผลตอบแทนผู้ถือหุ้น (ROE) ต่ำกว่าเกณฑ์
อัตราผลตอบแทนผู้ถือหุ้น (ROE) ลดลงอย่างมีนัยยะสำคัญ
อัตราผลตอบแทนสินทรัพย์ (ROA) ค่อนข้างต่ำเมื่อเทียบกับอัตราผลตอบแทนผู้ถือหุ้น(ROE)
อัตราเร่งของการเติบโตของอัตราผลตอบแทนสินทรัพย์ (ROA) ต่ำกว่าเกณฑ์
อัตราเร่งของการเติบโตของอัตรากำไรสุทธิ ต่ำกว่าเกณฑ์
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
ถ้าดูอย่างละเอียดจะพบว่า ปัจจัยทางคุณภาพ ยังไม่ดีนัก สุขภาพทางการเงิน ไม่ดี และ ประสิทธิภาพการทำกำไร ดี , ...
| ปัจจัยทางคุณภาพ |
|
51% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 99 |
| Magic Formula Rank by ROA |
794
|
| Magic Formula Rank by ROE |
794
|
| Magic Formula Rank by ROIC |
889
|
| Price | 49.72 |
| PBV / Sector |
4.28 / 2.77
|
| Earning Per Share | 2.95 |
| PE / Sector |
16.86 / 23.60
|
| PEG or PE/Growth / Sector |
0.22 / 0.07
GREAT
|
| Average 1M Daily Value |
163.22 M
GREAT
|
| Average 1W Daily Value |
166.70 M
GREAT
|
| ปัจจัยทางเทคนิค |
|
42% |
| สุขภาพทางการเงิน |
|
47% |
| ประสิทธิภาพการทำกำไร |
|
75% |
| ผลตอบแทนต่อผู้ถือหุ้น |
|
54% |
| รายละเอียดการจดทะเบียน |
| Analyze Date | 2026-06-04 09:24:27 |
| Symbol | GSK |
| Name | GLAXOSMITHKLINE PLC ADR |
| Sector | Healthcare >> Drug Manufacturers - General |
| Market | NYSE |
| Listed Shares | 2,005.23 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 98,256.18 / 232,396.15 |
| ข่าว, ประมาณการ, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 79 New Oxford Street, London, United Kingdom, WC1A 1DG
Phone: 44 20 8047 5000
Website: https://www.gsk.com
Employees: 66,841
Description: GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, inflammation, and inhaled medicines for HIV, respiratory eosinophildriven diseases, lupus and lupus nephritis, ovarian cancer, and endometrial cancer. It also provides vaccines for Shingles, Meningitis, RSV, Seasonal Influenza, Hepatitis, Diphtheria, Tetanus, Acellular Pertussis, Rotavirus, Pertussis, Polio, Haemophilus, Invasive Diseases, Pneumonia, Acute Otitis Media, Measles, Mumps, Rubella and Chickenpox, and Human Papilloma Virus. Additionally, the company offers general medicines for asthma, COPD, bacterial infection, benign prostatic hyperplasia, allergic rhinitis, and inflammatory skin conditions. It also focuses on the discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. It has a collaboration agreement with CureVac to develop mRNA vaccines for infectious diseases. The company has a strategic alliance with AN2 Therapeutics, Inc. for the development of new therapies for TB. GSK plc was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. The company was founded in 1715 and is headquartered in London, United Kingdom.
ME vs SECTOR Healthcare >> Drug Manufacturers - General
Click a bubble to view stock details · Bubble size represents market capitalization share
Google